Islet cell xenotransplantation: A serious look toward the clinic

Xenotransplantation

Volumn 21, Issue 3, 2014, Pages 221-229

  Samy, Kannan P ^a   Martin, Benjamin M ^a   Turgeon, Nicole A ^a   Kirk, Allan D ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

artificial pancreas; clinical trial; ethics; genetically engineered animals; immunosuppression; islet transplantation; xenotransplantation

Indexed keywords

ALLOTRANSPLANTATION; DIABETIC PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PANCREAS TRANSPLANTATION; PRIMATE; PRIORITY JOURNAL; REVIEW; SURVIVAL; SWINE; XENOTRANSPLANTATION; ANIMAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; PANCREAS ISLET TRANSPLANTATION; PATIENT SELECTION; PROCEDURES; XENOGRAFT;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; PATIENT SELECTION; PRIMATES; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84901838525     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12095     Document Type: Review

References (74)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
3. Leitao CB, Cure P, Tharavanij T, Baidal DA, Alejandro R,. Current challenges in islet transplantation. Curr Diab Rep 2008; 8: 324-331.
4. Frank A, Deng S, Huang X, et al. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004; 240: 631-640; discussion 40-3.
5. www.citrregistry.org. Collaborative Islet Transplant Registry 2010 Annual Report. December 30, 2011.
6. Dufrane D, Gianello P,. Pig islet for xenotransplantation in human: structural and physiological compatibility for human clinical application. Transplantat rev 2012; 26: 183-188.
7. Buhler L, Deng S, O'Neil J, et al. Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation 2002; 9: 3-13.
8. Kirchhof N, Shibata S, Wijkstrom M, et al. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation 2004; 11: 396-407.
9. Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
10. Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301-303.
11. Ayares D, Phelps C, Vaught T, Ball S,. Genetic engineering of pig islets for improved transplant outcomes. Xenotransplantation 2007; 14: 428.
12. Cardona K, Milas Z, Strobert E, et al. Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7: 2260-2268.
13. Rood PP, Bottino R, Balamurugan AN, et al. Reduction of early graft loss after intraportal porcine islet transplantation in monkeys. Transplantation 2007; 83: 202-210.
14. Russell MC, Cardona K, Olivia VL, et al. Engraftment of neonatal porcine islets in diabetic non-human primates by blockade of the CD28/CD40 costimulatory pathways. Xenotransplantation 2007; 14: 423.
15. Casu A, Bottino R, Balamurugan AN, et al. Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: implications for translation into clinical practice. Diabetologia 2008; 51: 120-129.
16. Hecht G, Eventov-Friedman S, Rosen C, et al. Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci USA 2009; 106: 8659-8664.
17. van der Windt DJ, Bottino R, Casu A, et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716-2726.
18. Thompson P, Badell IR, Lowe M, et al. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant 2011; 11: 2593-2602.
19. Thompson P, Cardona K, Russell M, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011; 11: 947-957.
20. Thompson P, Badell IR, Lowe M, et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant 2012; 12: 1765-1775.
21. Lowe MC, Badell IR, Turner AP, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant 2013; 13: 312-319.
22. Groth CG,. Heading towards an application of pig-to-man islet transplantation. Xenotransplantation 2009; 16: 193.
23. Hering BJ, Cooper DKC, Cozzi E, et al. Executive summary. Xenotransplantation 2009; 16: 196-202.
24. Cooper DK, Bottino R, Satyananda V, Wijkstrom M, Trucco M,. Toward clinical islet xenotransplantation-are revisions to the IXA guidelines warranted? Xenotransplantation 2013; 20: 68-74.
25. van der Windt DJ, Bottino R, Kumar G, et al. Clinical islet xenotransplantation: how close are we? Diabetes 2012; 61: 3046-3055.
26. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999; 67: 846-854.
27. Marigliano M, Bertera S, Grupillo M, Trucco M, Bottino R,. Pig-to-nonhuman primates pancreatic islet xenotransplantation: an overview. Curr Diab Rep 2011; 11: 402-412.
28. Hering BJ, Walawalkar N,. Pig-to-nonhuman primate islet xenotransplantation. Transpl Immunol 2009; 21: 81-86.
29. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I,. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 2008; 86: 10-15.
30. Gangappa S, Larsen CP,. Immunosuppressive protocols for pig-to-human islet transplantation: lessons from pre-clinical non-human primate models. Xenotransplantation 2008; 15: 107-111.
31. Badell IR, Russell MC, Thompson PW, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Investig 2010; 120: 4520-4531.
32. Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010; 90: 1595-1601.
33. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010; 10: 2082-2091.
34. Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S,. Efalizumab. Expert Opin Drug saf 2011; 10: 239-251.
35. Cooper DK, Tseng YL, Saidman SL,. Alloantibody and xenoantibody cross-reactivity in transplantation. Transplantation 2004; 77: 1-5.
36. Basnet NB, Ide K, Tahara H, Tanaka Y, Ohdan H,. Deficiency of N-glycolylneuraminic acid and Galalpha1-3Galbeta1-4GlcNAc epitopes in xenogeneic cells attenuates cytotoxicity of human natural antibodies. Xenotransplantation 2010; 17: 440-448.
37. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
38. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089-1092.
39. Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 2004; 101: 7335-7340.
40. Lutz AJ, Li P, Estrada JL, et al. Double knockout pigs deficient in N-glycolylneuraminic acid and Galactose alpha-1,3-Galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013; 20: 27-35.
41. Komoda H, Miyagawa S, Omori T, et al. Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 2005; 12: 209-216.
42. Jang K-S, Kim Y-G, Adhya M, Park H-M, Kim B-G,. The sweets standing at the borderline between allo- and xenotransplantation. Xenotransplantation 2013; 20: 199-208.
43. Burlak C, Bern M, Brito AE, et al. N-linked glycan profiling of GGTA1/CMAH knockout pigs identifies new potential carbohydrate xenoantigens. Xenotransplantation 2013; 20: 277-291.
44. Iwase H, Ekser B, Hara H, et al. Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition. Xenotransplantation 2014; 21: 72-83.
45. Miwa Y, Yamamoto K, Onishi A, et al. Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 2010; 17: 26-37.
46. Ko N, Lee JW, Hwang SS, et al. Nucleofection-mediated alpha1,3-galactosyltransferase gene inactivation and membrane cofactor protein expression for pig-to-primate xenotransplantation. Anim Biotechnol 2013; 24: 253-267.
47. Hurh S, Cho B, You DJ, et al. Expression analysis of combinatorial genes using a bi-cistronic T2A expression system in porcine fibroblasts. PLoS ONE 2013; 8: e70486.
48. Martin B, Thompson P, Lowe M, et al. Novel Dual Transplant Model: In Vivo Evaluation of Gal-Deficient and Wild-Type Xenoislet Preparations within a Single Recipient. Am J Transplant 2012; 12: 478.
49. O'Connell PJ,. Chapter 6: Patient selection for pilot clinical trials of islet xenotransplantation. Xenotransplantation 2009; 16: 249-254.
50. Graham ML, Schuurman HJ,. The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival. Xenotransplantation 2013; 20: 5-17.
51. Mueller KR, Balamurugan AN, Cline GW, et al. Differences in glucose-stimulated insulin secretion in vitro of islets from human, nonhuman primate, and porcine origin. Xenotransplantation 2013; 20: 75-81.
52. Dufrane D, Gianello P,. Pig islet xenotransplantation into non-human primate model. Transplantation 2008; 86: 753-760.
53. Boneva RS, Folks TM,. Xenotransplantation and risks of zoonotic infections. Ann Med 2004; 36: 504-517.
54. Wilson CA,. Porcine endogenous retroviruses and xenotransplantation. Cell Mol Life Sci 2008; 65: 3399-3412.
55. Argaw T, Wilson CA,. Detailed mapping of determinants within the porcine endogenous retrovirus envelope surface unit identifies critical residues for human cell infection within the proline-rich region. J Virol 2012; 86: 9096-9104.
56. Mattiuzzo G, Takeuchi Y, Scobie L,. Potential zoonotic infection of porcine endogenous retrovirus in xenotransplantation. Methods Mol Biol 2012; 885: 263-279.
57. Mazurek U, Kimsa MC, Strzalka-Mrozik B, et al. Quantitative analysis of porcine endogenous retroviruses in different organs of transgenic pigs generated for xenotransplantation. Curr Microbiol 2013; 67: 505-514.
58. Semaan M, Rotem A, Barkai U, Bornstein S, Denner J,. Screening pigs for xenotransplantation: prevalence and expression of porcine endogenous retroviruses in Gottingen minipigs. Xenotransplantation 2013; 20: 148-156.
59. van der Laan LJ, Lockey C, Griffeth BC, et al. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature 2000; 407: 90-94.
60. Patience C, Takeuchi Y, Weiss RA,. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282-286.
61. Denner J, Mihica D, Kaulitz D, Schmidt CM,. Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs). Virol J 2012; 9: 260.
62. Waechter A, Denner J,. Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV). Immunol Res 2014; 58: 9-19.
63. Waechter A, Eschricht M, Denner J,. Neutralization of porcine endogenous retrovirus by antibodies against the membrane-proximal external region of the transmembrane envelope protein. J Gen Virol 2013; 94: 643-651.
64. Shah KV,. Simian virus 40 and human disease. J Infect Dis 2004; 190: 2061-2064.
65. Pareta RA, Farney AC, Opara EC,. Design of a bioartificial pancreas. Pathobiology 2013; 80: 194-202.
66. Ricotti L, Assaf T, Dario P, Menciassi A,. Wearable and implantable pancreas substitutes. J Artif Organs 2013; 16: 9-22.
67. Borg DJ, Bonifacio E,. The use of biomaterials in islet transplantation. Curr Diab Rep 2011; 11: 434-444.
68. Lutolf MP, Hubbell JA,. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005; 23: 47-55.
69. Teramura Y, Iwata H,. Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. Adv Drug Deliv Rev 2010; 62: 827-840.
70. Elliott RB, Escobar L, Tan PL, et al. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transpl Proc 2005; 37: 3505-3508.
71. Sasikala M, Rao GV, Vijayalakshmi V, et al. Long-term functions of encapsulated islets grafted in nonhuman primates without immunosuppression. Transplantation 2013; 96: 624-632.
72. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci 2013; 110: 19054-19058.
73. Dufrane D, Gianello P,. Macro- or microencapsulation of pig islets to cure type 1 diabetes. World J Gastroenterol 2012; 18: 6885-6893.
74. Garkavenko O, Durbin K, Tan P, Elliott R,. Islets transplantation: New Zealand experience. Xenotransplantation 2011; 18: 60.